author index - drug metabolism and...
TRANSCRIPT
AUTHOR INDEX
Abramson. Fred P.. 46
Abuchowski. A.. 349Adedoyin. Adedayo. 271Aitio. Antero. 303Albert. Adelin. 437
Albucher. Ronald C., 585Anderson. Lucy M.. 733
Ando. Hidehiro, 740Andreoli. Vittorino. 263
Andres. Herbert R.. 382Arison. Byron H.. 590Astoin. Jacques, 654Augustine. James A.. 73
B#{228}#{224}rnhielm.C.,613
Baba. Shigeo. 509Backman. A., 613Baillie, Thomas A.. 221. 443. 454.
654
Barber. Harold E.. 482Barinov. Irma. 430Bartels. M. J.. 97
Bartsch.H.. 118
Beaune, Philippe H.. 437Bellward. Gail D.. 366Bend, John R.. 303
Benet. Leslie Z.. 503B#{233}r#{233}ziat.J. C.. 1 18Berger. J. A.. 147Bergstrom. Richard F.. I 75Besner, Jean-Guy. 246Bezek. Stefan. 718
Bhatia. Ashok V.. 303
Bialer. Meir. 132. 250Bickel. M. H.. 361Bickers. David R.. 413. 637
Biglino. G.. 267Birnbaum. L. S., 417Birnbaum. Linda S.. 34Bitar. Milad S.. 585
Borghoff. S. J.. 417
Brammer. James D.. 386Branch, Robert A., 627Braselton. Jr.. W. Emmett. 166Breimer, D. D., 331. 601Bressler. R.. 59
Brown. Jr., Robert A.. 79Brown. N. S..349
Brun.G.. 118
Buhs. Rudolf P.. 590Buijs. W.. 608
Bullingham, R. E. S.. 230Burd#{225}t�,Peter. 718
Busch. N.. 147
Bygdeman. Marc. 494
Calabrese. Edward. 372Callaghan. John T.. I 75Camus.A.-M.. 118
Canada. Andrew. 372
Canfell. P. Claver. 703
Canova-Davis. E.. 643Carbone. J. J.. 325
Castagnoli, Jr.. Neal. 703Castegnaro, M.. 1 18
Chabard. J. L., 147Chang,S.-L.. 281
Chiang. J. Y. L.. 643Chiu, Shuet-Hing Lee, 590
Christensen. Niels J., 494Cocchetto. David M., 649Colby. Howard D.. 549Coon. Minor J.. 89Cooper. Thomas B.. 692Corcoran, George B.. 674Crooks, Peter A.. 574
Crul, I. E. P., 331
Damani, Lyaquatali A.. 574
Darland, Gary K., 668
Das, Mukul. 637, 413De Graeve, Jean, 437de Lannoy, In#{233}sA.M., 513Della Corte, Laura, 263Devereux, Theodora R., 319Dickinson, Ronald G., 255Dills, R. L.. 190
Dimov, Vladimir. 494Dizio. Deborah P., 631Don. Philip S. C.. 413
Dostal. Lori A.. 303Duggan, Daniel E., 649Dulik,DeanneM., 313
Dumont. Pierre, 477
Duprat. J., 1 12Duri�,ov#{225},Maria, 718du Souich, Patrick, 663
Eacho. Patrick I.. 526Eadie, Mervyn J.. 255
Enreille, A., 147Erill. Sergio. 663
Faberov#{225},Viera, 718Fahey, Mark R.. 703Fayz.Shirin, 102
Fenselau. Catherine. 313Fenselau, Catherine C., 197Ferguson, Ronald J., 566
Forster. U., 353
Fouts. James R.. 319Franc, Michel, 137
Franzone, J. S., 267Fujita. Shoichi, 277
Funk. Mary L.. 555
Galtier. Pierre, 137Garrettson. L. K., 619
Garvie. Clare, 540Gerardy. Bruno M.. 477
Gerkens. John. 627
Gerster, John F., 555
Gillette. J. R.. 559Godeneche. D.. I 12Gombar. Charles T.. 540
Gordon, W. Perry. 443, 454Gorsky. Lee D., 89Green, Krister, 494Green, Marilyn, 590Grosa,G., 267
Gross, Brion, 392
Grossman, Scott J.. 689Guengerich, F. Peter, 437Guenthner, M., 208Gutzait, Louis, 540
Hagiwara, Akihiro, 733Hajdu, Richard, 668Hamilton. Marta, 5
Hansen, Alfred R., 555
Hansen, Chad S., 555
Harigaya, Shoichi, 740Harrington, George W., 733
Harris, Craig. 303
Harrison, Lester I., 555
Harvey, D. J., 230
Hawksworth, Gabrielle M., 482
Hayton, W. L., 299
Heald, Anthony F.. 631
Hee, Shane S. Que, 65Hem, David W., 566Hekman, Peter. 370Hennis, Pim J., 703Hernandez, Oscar. 303Hietanen,E., 118
Hilbert, James M.. 310Hill, D. L.. 698Ho, D. H., 349HofFmann, K. J., 613Hoffmann, Kurt-JUrgen, 336, 341Holmes, R.. 349Hooper, Wayne D., 255
Homing, E. C., 97Horning,M.G..97Houdi, Abdulghani A.. 574
Houston. J. Brian, 237Hultin, Theresa A.. 714
Idle,J.R., 118Igwe,OrisaJ., 65
Jacob. Theodore A., 590Jacqz, Evelyne, 627James. Margaret 0., 471
Johnson. Raymond, 627Jollow, David J., 25, 689Joseph, Gerald. 540Juchau, Mont R.. 287. 293
Kahan, Frederick M., 668Kaminsky, Laurence S., 437Kantrowitz, Joel D.. 132Kapusta, Dominique, 477
Karnezis, Thomas A.. 208Kasuya. Yasuji. 509Kawai, Ryosei, 277Keating, M., 349
750
Keith, Richard A., 680
Kerremans, Adrian L., 680Kick, Constance J., 430Kirkland, Karin M., 631Kirlin, Ward G.. 566
Kissinger. Peter T., 5Kitteringham, N. R., 142Klaassen, C. D., 190Kluck, Ruth M., 255Knadler, Mary Pat, 175Kobusch, Adriane B., 663Kolis, Stanley J., 465Komiskey. H. L., 299Komiya, Izumi, 239
KrakofT� I. H., 349Kremers, Pierre G., 437Kropp, Helmut, 668
Kumano, Tomomi, 487
LaCagnin, Lynn B., 549Larrieu, Gilberte, 127
Layton, W. John, 574Leinweber, F.-J., 59, 325Lepage, Francis, 654
Leuschner, J. T. A., 230Levandoski, Patricia, 540Levine.W.G., 19
Levine, Walter G., 13Levy, R. H., 281Levy, Ren#{233}H., 443, 454. 654
Liberato, D. J., 559Lin, Jiunn H., 649
Lisek, Carol A., 313Liu, Ann L., 430
Lockard, Joan S.,443Loewen, Gordon R., 127Loftus, Philip, 631
Loh, A. C., 59, 325Luippold,G., 353Lutz, Michael P., 46
MacLeod, James N., 585Madelmont, J. C., I 12
Magee, Peter N., 733Maggs,J.L., 142Majesky, Mark W.. 293Malaveille, C., I 18
Malbica,Joseph0., 631
Mamada, Kumiko, 509Manis, Melanie 0., 166Mannering, Gilbert J., 1Marcelo, Cynthia L., 413Marko, Vladimir, 718Massarella, J. W., 59Massey, Thomas E., 319May, Cynthia M., 714Mayersohn, Michael, 52
McKay, Gordon, 127Meacham, Jr., Roger H., 430Mehendale, Harihara M., 423Meloche, Sylvain, 246Meyniel, G., I 12Michelon, J., 1 18
AUTHOR INDEX 751
Mico.BruceA.. 540Miller, Ronald D., 703Minor.L.D..214
Mitchell, A. D.. 155, 161Mitchell, Edgar W., 79Modly. Charlotte E.. 413Moneti. Gloriano, 263
Moody. David E.. 709
Moon, Richard C., 7 14Moreau,M.F.. 112
Moreland, Terence A., 654
MUhlebach. S.. 361Mukhtar. Hasan. 413, 637Mulder, Gerard J.. 102
Nagata,K., 559
Nakano, Kozaburo, 740Namkung. Moses J.. 287. 293
Nardini, Marcello, 263Nelson. Wendel 1., 202. 287, 506Newman, R. A.. 349Nicholson. J. K.. 746Ninci. Rossana. 263Ning,James, 310
Noordhoek. J., 622
Ober, Robert E., 555O’Donnell, John P., 549Oei, I. H.. 601
Ogolla, Frederick, 566Ohashi, Motoaki, 740Olovson, Stig-Garan, 336Onkenhout, W., 601, 608
Otterness, Diane M.. 680Overton, B. W., 619Owens. S. Michael, 52
Pallante, Sharon L.. 313Pang. K. Sandy. 102, 513
Parandoosh. Z., 643Park, B. K., 142Paton, W. D. M., 230Paulson,G. D., 155, 161
Perumal, Authur S., 692Philpot, R.. 643Piotrovsky. Levon B.. 718
Plagne.R.. 112Pognat, J. F.. 147
Pool, William F., 574
Postma, Edward J., 465Potts, Brian D., 540
Poupaert, Jacques H., 477
Price, Veronica F., 25Prickett, Kathryn S., 22 1, 443, 454Puyear, Robert L., 386Pylypiw. Jr., Harry M., 733
Quistad, Gary B., 521
Rahimtula, A. D., 724
Rahman, A., 299
Raza,H., 19Redegeld, F. A. M., 622
Renberg, Lars, 336
Rettenmeier, Albert W., 443, 454Rice, Susan A., 392Roberts, Stanley A.. 25Rohlfing, Stephen R.. 555
Rubin, Alan, 175Ruelius, Hans W., 430Russel, Frans G. M., 370
Salhab, Abdulazim S., 471Sandor, D., 59
Sasame,H.A., 559
Sasso, G. J.,325
Sasso,GinoJ., 465
Schanker, Lewis S., 79Schenker, Stephen, 627Schillings, Roger T.. 405Schooley, David A., 521Schuppan, Dietrich. 555Schwarz, L. R.. 353Serra, Mauricio T., 392Sestokas, Elena, 590Sestokas, Ruta, 590
Sgaragli, Giampietro, 263Shamsuddin. Z. A.. 724Shapiro. Bernard H.. 585Shargel, Leon. 580
Shaw, P. Nicholas, 271Shealy, Y. F.. 698Shetty, H. Umesha. 506Shih. T. W.. 698Shipley, Lisa A.. 526
Shiverick, Kathleen T., 471
Sintov. Amnon, 250
Sisenwine, Samuel F.. 41, 405, 430Smith, Philip C., 503Smith, Thomas M., 692
Smuckler. Edward A., 709Some, P. J., 619Some. W. H.. 619
�olt#{233}s,Ladislav. 718Somani, Satu M.. 183
Staiger. Luana E., 521Straub. Kenneth, 540Strother, D. L., 698
Suckow, Raymond F.. 692
Sugawara, Yoichi, 740Sultatos. L. G., 214Sunahara, Geoffrey I., 366
Suzuki, Tokuji, 277Swagzdis, James, 540Sweeny, David J., 526Symchowicz, Samson, 310Szuna, A. J., 59. 325
Talaat, Rasmy E., 202Taub, Rae, 590Taylor. Lorna A., 709Taylor, Wesley G.. 532te Koppele, Johan, M., 102Thompson, Linda K., 566Thummel, Kenneth E.. 443Tilley. J. W., 325
Timbrell, J. A., 746Tio, Cesario 0., 41
Tlach. Christine, 625
Tombret, Francis. 654Tonelli, Alfred P., 132
Toome.V., 325Trinidad. Alma, 566Trnovec, Tom#{225}s,718
Troke, J., 746Tseti. Julia, 271Tufenkji, Ala Eldin, 137
Tulip, K., 746
U. S.-W. Ernest, 674
Uematsu, Takayoshi, 487
Unni, Latha K., 183
Valoti, Massimo, 263
van Breemen, Richard B., 197VandenHeuvel, J. A., 668VandenHeuvel, William J. A., 590van Der Gen, A., 601van der Gen, A.. 608VanDerGraaff,M., 331
van Ginneken, Cees A. M.. 370
van Loon, W. M. G. M., 608van Meerteren-W#{228}lchli, B., 601Verbeeck, Roger K.. I 27Vermeulen, N. P. E.. 331. 608
Wagner, William D., 65Walker, Kim A., 482
Walker, Robert W., 668Wallace, Kendall, B., 399
Wang, Shoou-Lih, 392, 471Warburton, Susan, 271Ward, Stephen, 627Waskell, L., 643Weber. Wendell W., 377, 382Weidolf,L.,6l3Weiner, Myron. 526Weinshilboum, Richard M.. 680Weisenburger, W. P., 299Williams, T. H., 59, 325Williams, Thomas H., 465Wilson, I., 746Wilson, John, 372
Wong. Bradley K., 674Wood, Brian T., 255Wyss. P. A., 36 1
Yacobi, Avraham, 132
Yagen, Boris, 250
Yang, Hsueh-Ying L.. 287, 293Yee, Nelson S.. 580
Yeh, Kuang C.. 649Yen, A., 349Yoshioka. Tadao, 487
Young, Robert A., 423
Yuen, Vincent, 102
Zampaglione, Nicola, 310
Zaylskie, R. G., 155Zemaitis, Michael A., 73Zem#{225}nek,Mari#{225}n,718Zoetemelk, C. E. M., 601Zysset, Thomas, 625
752
SUBJECT INDEX
Acetaminophen
absorption and metabolism. in situ perfused small intestine (rats). 102disposition. overfed rat model. obese humans. 674hepatoxicity. cobalt chloride-induced protection (hamsters). 25
Acetanilide. aniline metabolism (rats). 6892-Acetylaminofluorene. acetylator genotype. carcinogen metabolism
(hamsters). 566
Acetylationacetylator genotype. carcinogen metabolism (hamsters). 566hereditary. polymorphisms. molecular basis (rabbits. hamsters. hu-
mans). 377oxidation or. seromucoids (rats). 663
predictors for polymorphism (rabbits). 382M-Acetyl-�-dinitrophenyl-lysine. novel metabolite. covalently modified
proteins in t’it’o (rats). 142
a-Acid glycoprotein. antipyrine clearance and. rifampin induction. ki-
netics (dogs). 46
l-O-Acyl glucuronides. 4-(p-nitrobenzyl)pyridine. reaction with, 197Adenine nucleotides. dibutyryl cyclic AMP. inhibited glucuronidation
and sulfation. hepatocytes (rats. guinea pigs). 526
Adenosine 3’-phosphate-5’-phosphosulfate. hepatic glutathione and
UDP-glucuronic acid. decreased energy production (rats). 190Adipose tissue. constant mass. 2.2’.4.4’.5.5’-hexachlorobiphenyl. long-
term pharmacokinetics (rats). 361
Aging
allyl isothiocyanate. metabolism and excretion (rats). 417
diazepam. changes in distribution and metabolites (rats). 299sex effects and. theophylline. elimination kinetics (rabbits). 372
Aglycosylation. disposition of doxorubicin. isolated liver nuclei andmicrosomes, 399
Ah locus. effect. 2.3.7.8-tetrachlorodibenzo-p-dioxin. distribution and
excretion (mice). 34Alkene oxide. polycyclic arene and. glutathione-S-transferases. stereose-
lectivity (rats). 303Allyl isothiocyanate. metabolism and excretion. age-related changes
(rats). 4172-Am i nolluorene. acetylator genotype, carcinogen metabolism (ham-
sters). 566Aminopyrine. pharmacokinetics. hepatic blood flow (rats). 625Amiodarone. metabolism. liver and small intestine (rabbits. rats). 423Amoharbital. N-glycosylation. product enantioselectivity (humans). 619Androgen. cytosolic binding assays. testosterone metabolism. liver (rats),
366
Aniline. metabolism. use of NIH shift (rats). 689Antiepileptic drugs. stiripentol. metabolic fate (humans). 654Anti-inflammatory agents. disposition of(5//-dibenzo [a.d]cyclohepten-
5-vlidene)acetic acid (rats. mice. monkeys. dogs). 405
Antipyrine. metabolite formation. inhibition. cimetidine and metyra-pone(rats). 271
Antipyrine clearance. a-acid glycoprotein and. rifampin induction. ki-
netics (dogs). 46
Aorta
glucuronidation. carcinogens. atherogens (rats. cockerels. man). 293sulfation. carcinogens. atherogens (rats. cockerels. man). 287
Arene. polycyclic. alkene oxide substrates and. glutathione S-transferasestereoselectivity (rats). 303
Arthritis. adjuvant-induced. propranolol. altered disposition (rats). 482Arylamine. N-acetylation polymorphism. predictors (rabbits). 382
Atherogens phase II biotransformation cultured aortic tissues andcells (rats. cockerels. man). 287, 293
Benzo(a)pyrenebenzo(a)pyrene 7.8-diol and. metabolism in epidermis (mice). 637
inhibited metabolism. capsaicin. DNA binding in keratinocytes (rats.
humans). 4 I 3positional metabolism. placenta and maternal liver (rats). 471
Benzodiazepines. inhibition of ciramadol glucuronidation (dogs), 430Biliary excretion
impaired. valproic acid. /f-glucuronidase resistant “glucuronides”
(rats). 255isotretinoin glucuronide metabolism (rats). 246metabolite kinetics. enalaprilat. diffusional barrier (rats), 513
trimoprostil metabolites. oxidation and taurine conjugation (rats). 465
Blood flow. hepatic. aminopyrine pharmacokinetics (rats). 625
Brain. plasma and. bupropion and metabolites (rats. mice, guinea pigs).692
Brodie Award. from morphine to interferon. odyssey ofdrug metabolism.
Bupropion. metabolites and. plasma and brain (rats. mice, guinea pigs),
692
Capsaicin. benzo(a)pyrene metabolism. DNA binding. keratinocytes(rats. humans). 413
Carbamazepine. carbamazepine-lO. 1 1-epoxide and. valproic acid. inhibi-tory effect (rats). 281
Carbon tetrachloride. induced cytochrome P-450 loss. immunohisto-
chemistry (rats). 709Carcinogens
metabolism
acetylator genotype (hamsters). 566debrisoquine. DA and Lewis rats. 1 18
phase II biotransformation. cultured aortic tissues and cells (rats.cockerels). 287
phase II biotransformation. cultured aortic tissues and cells (rats.cockerels. man), 293
Carnitine. role in conjugation. acidic xenobiotics (rats), 521
Cephalosporin. CL 284.635. serum protein binding. various species. 132CERM 35 I 7. mociprazine. N-dephenylation (dogs). 1472-Chloroethyl nitrosocarbamoylcystamine. metabolism, liver, subcellular
fractions(rats). I 126-Chloro-2.3.4.5-tetrahydro-3-methyl-l H-3-benzazepine. pharmacoki-
netics, metabolism and disposition (rats, dogs). 540Chlorpromazine. major plasma metabolite. promazine. chronic schizo-
phrenics (man), 263Chromatography. metabolic disposition. laudanosine (dogs. rabbits. hu-
mans). 703Cibenzoline
disposition and metabolic fate (man). 59metabolism (dogs. rats). 325
Cimetidinedrug interaction (rats). 649metyrapone and, antipyrine metabolite formation. inhibition (rats).
271ranitidine or. pretreatment. hepatic mixed function oxidase activity
(rats). 580Ciramadol. inhibited glucuronidation. benzodiazepines (dogs). 430
CL 284.635. cephalosporin. serum protein binding. various species. 132Clofibrate. N, N-dimethyl-4-aminoazobenzene. azoreduction, hepatic mi-
crosomes (rats). I 9Cobalt chloride. induced protection. hepatoxicity. acetaminophen (ham-
sters). 25
Cycloprate. role of carnitine. conjugation. acidic xenobiotics (rats). 521Cyclopropanecarboxylic acid. role of carnitine. conjugation. acidic xc-
nobiotics (rats). 521Cyclosporin A. effects. hepatic microsomal drug metabolism (rats). 73Cytochrome b5. reconstitution. effects of conditions. cytochrome P-450-
catalyzed reactions (rabbits). 89
Cytochrome P-450amiodarone metabolism. liver and small intestine (rabbits, rats). 423catalyzed reactions. cytochrome b5 reconstitution. effects of conditions
(rabbits). 89
SUBJECT INDEX 753
CC14-induced loss. immunohistochemistry (rats), 709
destruction. liver microsomes and, valproic acid metabolism (rats).
221isozyme concentrations. monooxygenase activities. liver microsomes
(humans). 437methoxyflurane. enzymes catalyzing metabolism (rabbits). 643
Debrisoquine, carcinogen metabolism, DA and Lewis rats, 1 18
Defluorination. methoxyflurane and fluoroacetate. hepatic cytosolic en-zymes (rats). 392
Deuterium labelingpharmacokinetic equivalence. phenytoin. 509
propranolol. stereoselective metabolism, 506Diazepam. changes in distribution and metabolites. aging (rats). 299
(511-Dibenzo [a.djcyclohepten-5-ylidene)acetic acid. disposition (rats.
mice. monkeys. dogs), 405l.4-Dibromobutane. biotransformation. sulfur metabolites (rats). 608I .2-Dibromopropane. biotransformation (rats). 601Dibutyrl cyclic adenosine 3’:5’-monophosphate. inhibited glucuronida-
tion and sulfation, hepatocytes (rats, guinea pigs), 526Dibutyryl cyclic guanosine 3’:5’-monophosphate, dibutyryl cyclic AMP.
inhibited glucuronidation and sulfation, hepatocytes (rats. guineapigs). 526
w-Diethylamino-2-hydroxymethyl-6-methylacetanilide. new lidocainemetabolite (rats). 277
N.N-Diethyl-meta-toluamide. metabolism, liver microsomes (rats). 532Diflunisal sulfate. new major metabolite. isolation and identification
(man). 127N.N-Dimethyl-4-aminoazobenzene
azoreduction. hepatic microsomes (rats). I 9thiol environment regulation. liver microsomes (rats). I 3
2.6-Dimethylnaphthalene. metabolism by liver microsomes, glutathione
depletion (rats). 724I 6. 16-Dimethyl-trans-prostaglandin E, methyl ester. metabolism. intra-
venous and vaginal administration. pregnant women, 494Disulfiram, pretreatment effect. ethylene dichloride. distribution (rats).
65
DNA. binding in keratinocytes. capsaicin. inhibited benzo(a)pyrene me-
tabolism (rats, humans). 413Doxophylline. metabolism, liver microsomes (rats), 267Doxorubicin. disposition. aglycosylation. isolated liver nuclei and micro-
somes. 399
Enalapril. metabolite kinetics. enalaprilat. diffusional barrier (rats). 513
Enalaprilat. metabolite kinetics. diffusional barrier (rats). 513
Enantioselectivity. N-glucosylation of amobarbital (humans). 619Enzymes
drug-metabolizing. experimental fascioliasis. liver (lambs). 137hepatic cytosolic. defluorination. methoxyflurane and fluoroacetate
(rats). 392immobilized. synthesis and characterization, fast atom bombardment
mass spectrometry (rabbits). 313induction. cultured hepatocytes (rats). 353
Epidermis. metabolism. benzo(a)pyrene and benzo(a)pyrene 7.8-diol
(mice). 637Epoxide hydrolases. multiple. lung (man). 208Ethanol. N-nitrosodimethylamine. tissue levels and biological effects
(mice). 733
Ethimizol. disposition (rats. mice). 718Ethylene dichloride. distribution. disulfiram. pretreatment effect (rats).
65N-Ethyl-in-hydroxymethylbenzamide. N.N-diethyl-meta-toluamide. me-
tabolism. liver microsomes (rats). 532N-Ethyl-in-toluamide. N,N-diethyl-meta-toluamide. metabolism. liver
microsomes (rats). 532
Fab fragments. phencyclidine-specific. phencyclidine disposition altera-tion (dogs). 52
Famotidine. drug interaction (rats). 649
Fascioliasis. experimental. drug-metabolizing enzymes, liver(lambs). 137Felodipine. biotransformation. liver microsomes (rats. dogs. man), 613Fludalanine. oxidative and defluonnative metabolism (rats), 663Flumequine. disposition (rats, dogs). 555Fluoroacetate. methoxyflurane and, defluorination. hepatic cytosolic
enzymes (rats), 392
2-2H-3-Fluoro-o-alanine. oxidative and defluorinative metabolism, flu-dalanine (rats). 663
Genetics. hereditary acetylation. polymorphisms. molecualr basis (rab-
bits. hamsters. humans). 377I .4t-r-Glucopyranosyl)amobarbital. product enantioselectivity (hu-
mans), 619
Glucuronidation
ciramadol. benzodiazepines (dogs). 430extrahepatic. morphine (dogs). 627inhibition. dibutyryl cyclic AMP. hepatocytes (rats. guinea pigs). 526
Glucuronides. �-glucuronidase-resistant. impaired bile elimination, val-proic acid (rats), 255
Glutathioneconjugates. immobilized enzyme synthesis. fast atom bombardment
mass spectrometry (rabbits). 313conjugation. allyl isothiocyanate metabolism. age-related changes
(rats). 417depletion. metabolism of 2.6-dimethylnapthalene, liver microsomes
(rats). 724l.2-dibromopropane biotransformation (rats). 601hepatic. UDP-glucuronic acid and adenosine 3’-phosphate-5’-phos-
phosulfate concentrations. decreased energy production (rats). 190Glutathione S-transferases. cytosolic, stereoselectivity. polycyclic arene
and alkene oxide substrates (rats), 303Growth hormone. deficiency. monosodium-L-glutamate, hepatic drug-
metabolizing enzymes (rats). 585
H2-antagonists. comparative effects. drug interaction (rats), 649Hepatocytes
i ndividual. xenobiotic biotransformation, microspectrofluorometry
(rabbits). 319inhibited glucuronidation and sulfation. dibutyryl cyclic AMP (rats.
guinea pigs). 526metabolite kinetics. enalaprilat. diffusional barrier (rats). 513primary cultures. induction. monooxygenase and UDP-glucuronosyl-
transferase (rats). 3531-lepatoxicity
acetam inophen. cobalt chloride-induced protection (hamsters). 25N-methylformamide. nuclear magnetic resonance (rats). 746N-nitrosodimethylamine. tissue levels and biological effects (mice),
7332,2’.4.4’.5.5’-Hexachlorobiphenyl. long-term pharmacokinetics. con-
stant adipose tissue mass (rats). 361Hopantenic acid. fl-glucoside. urinary metabolite ofcalcium hopantenate
(dogs). 740Hydrazaline. oxidative metabolism. liver microsomes (rats). 5492-Hydroxyacetanilide. metabolic product determination. liquid chro-
matography/electrochemistry (mice). 53-Hydroxyacetanilide. metabolic product determination. liquid chro-
matography/electrochemistry (mice), 5N-Hydroxy-2-acetylaminofluorene. acetylator genotype. carcinogen me-
tabolism (hamsters), 566I 7�1-Hydroxy-4.6-androstadiene-3-one. testosterone metabolite (rats).
5593-Hydroxy-benzo(a)pyrene
glucuronidation. carcinogens/atherogens. aortic tissues and cells (rats.cockerels. man). 293
sulfation. carcinogens/atherogens. aortic tissues and cells (rats. cock-erels. man). 287
para-H�droxymethadone. synthesis and characterization (rats). 477
754 SUBJECT INDEX
N-Hydroxy-N-acyl-aminobiphenyl ethers, chlorinated. cytosol-catalyzedtransacylation (rats), 487
N-(4-Hydroxyphenyl)-all-trans-retinamide, pharmacokinetics (rats,mice). 714
3-Hydroxysulfolane. 1,4-dibromobutane biotransformation (rats). 608
lmmunohistochemistry. cytochrome P-450 loss, carbon tetrachloride-induced loss (rats). 709
Indene, methylthio metabolite formation (guinea pigs. rats), 97
Interferon, morphine and, odyssey of drug metabolism, Brodie Awardlecture. 1
Intestine, smallamiodarone metabolism (rabbits. rats), 423
in situ perfused, acetaminophen absorption and metabolism (rats).102
Isomerization. all-trans- and 13-cis-retinoids, 698Isotretinoin glucuronide. metabolism. biliary excretion (rats), 246
Ivermectin, metabolic disposition (cattle. sheep. rats), 590
Kidneycarcinogen metabolism, debrisoquine, DA and Lewis rats, I 18isolated perfused. active tubular secretion, 1-naphthyl-�3-o-glucuronide
(rats), 622main urinary metabolites. identification. omeprazole oral dose (rats,
dogs). 3414,4’-methylenebis(2-chloroaniline), metabolism (dogs), 166renal clearance, urine flow dependence, drug properties (rats), 239
L-643,441. drug interaction (rats), 6493-(4-hydroxy-l-napthoxy)Lactic acid. synthesis and identification. pro-
pranolol metabolite. liver (rat. man), 202Laudanosine. metabolic disposition (dogs, rabbits, humans), 703Lidocaine. new metabolite. .,-diethylamino-2-hydroxymethyl-6-methy-
lacetanilide(rats),277Liquid chromatography. 2- and 3-hydroxyacetanilide, metabolic product
determination (mice), 5Liver
acetaminophen, cobalt chloride-induced protection (hamsters), 25
amiodarone metabolism (rabbits, rats), 423carcinogen metabolism. debrisoquine, DA and Lewis rats. 118drug-metabolizing enzymes
experimental fascioliasis (lambs), 137growth hormone deficiency. monosodium-L-glutamate (rats), 585
9000g supernatant fraction, 3-(4-hydroxy-l-napthoxy)lactic acid, syn-thesis and identification (rat, man). 202
isolated perfused, parathion, biotransformation factors (mice), 214
maternal, placenta and, benzo(a)pyrene positional metabolism (rats).471
metabolic fate of valproic acid (monkeys), 443, 454metabolite kinetics, enalaprilat, diffusional barrier (rats), 513
4.4’-methylenebis(2-chloroaniline), metabolism (dogs), 166microsomal drug metabolism, cyclosporin A effects (rats), 73mixed function oxidases, cimetidine or ranitidine pretreatment (rats).
580muscle clearance and. physostigmine (rats), 183N-(4-hydroxyphenyl)-all-trans-retinamide. pharmacokinetics (rats,
mice), 714
N. N-di methyl-4-aminoazobenzene, azoreduction, clofibrate induction(rats),19
subcellular fractions, 2-chloroethyl nitrosocarbamoylcystamine metab-olism (rats), I 12
testosterone metabolism, cytosolic androgen binding assays (rats), 366
thiol environment regulation. N,N-dimethyl-4-aminoazobenzene, mi-
crosomes(rats). 13thiol methyltransferase (mice), 680
Liver microsomescovalent binding, toluene metabolites (rats). 386cyclosporin A effects. drug metabolism (rats), 73
cytochrome P-450 destruction and. valproic acid metabolism (rats),
221doxophylline metabolism (rats), 267felodipine biotransformation (rats, dogs, humans), 613hydrazaline. oxidative metabolism (rats), 549metabolism of 2.6-dimethylnapthalene, glutathione depletion (rats),
724
methoxyflurane. enzymes catalyzing metabolism (rabbits), 643
monooxygenase activities, cytochrome P-450 isozyme concentrations
(humans), 437
N.N-diethyl-�neta-toluamide, metabolism (rats), 532
N.N-dimethyl-4-aminoazobenzene. azoreduction (rats), 19nuclei and. aglycosylation. doxorubicin disposition. 399propranolol. stereoselective metabolism, 506
testosterone. unusual metabolite (rats), 559Lung. drug absorption. species comparison, after aerosol inhalation or
intratracheal injection (mice. rabbits), 79
Mammary gland. N-(4-hydroxyphenyl)-all-trans-retinamide, pharmaco-kinetics(rats, mice). 714
Mass spectrometry. fast atom bombardment, glutathione conjugates,immobilized enzyme synthesis (rabbits). 313
Mercapturic acids. I ,2-dibromopropane biotransformation (rats), 601Methadone. para-hydroxymethadone, synthesis and characterization
(rats), 477Methoxyflurane
enzymes catalyzing metabolism (rabbits), 643fluoroacetate and. defluorination, hepatic cytosolic enzymes (rats), 392
4,4’-Methylenebis(2-chloroaniline), metabolism, liver and kidney slices
(dogs). 166N-Methylformamide. metabolism, nuclear magnetic resonance (rats),
746
N-Methyl-N’-oxonicotinium ion, isolation and characterization (guineapigs).574
16-Methylprogesterone, testosterone, unusual metabolite (rats), 559Methylthio metabolites. formation, indene (guinea pigs, rats), 97Metyrapone. cimetidine and. antipyrine metabolite formation, inhibition
(rats), 271Microsomes
2- and 3-hydroxyacetanilide metabolism. liquid chromatography/elec-trochemistry (mice), 5
liver. see Liver microsomesM icrospectrofluorometry. xenobiotics, biotransformation, individual
hepatocytes (rabbits), 319Mitochondria
energy production. effect of inhibitors, co-substrates (rats), 190fludalanine, oxidative and defluorinative metabolism (rats). 663
Mixed function oxidases, hepatic. cimetidine or ranitidine pretreatment
(rats), 580Mociprazine. CERM 35 17. N-dephenylation (dogs), 147
Monooxygenasecytochrome P-450 isozyme concentrations, comparison, liver micro-
somes (humans). 437growth hormone deficiency. monosodium-L-gluatmate, liver (rats),
585U DP-glucuronosyltransferase and. induction, hepatocyte primary cul-
tures (rats). 353Monosodium-L-glutamate. hepatic drug-metabolizing enzymes, growth
hormone deficiency (rats). 585Morphine
extrahepatic glucuronidation (dogs), 627interferon and, odyssey ofdrug metabolism, Brodie award lecture. 1
Muscle, clearance. hepatic and. physostigmine (rats), 183
l-Naphthyl-(1-D-glucuronide. active tubular secretion, isolated perfusedkidney (rats), 622
R-(�)-Nicotine, N-methyl-N’-oxonicotinium, isolation and characteriza-tion (guinea pigs). 574
SUBJECT INDEX 755
p-Nitroanisole. inhibited glucuronidation and sulfation. dibutyryl cyclicAMP, hepatocytes (rats. guinea pigs). 526
4-(p-Nitrobenzyl)pyridinel-O-acyl glucuronides reaction, 197
p-Nitrophenol. inhibited glucuronidation and sulfation. dibutyryl cyclic
AMP. hepatocytes (rats. guinea pigs). 526N-Nitrosodimethylamine. tissue levels and biological effects. ethanol
(mice). 733Nitrosourea. sulfur-containing. in vitro metabolism (rats). 1 12Nizatidine. H2-blocker. metabolism and disposition (humans). 175
Nootropic drugs. ethimizol disposition (rats. mice). 718Nuclear magnetic resonance
metabolism of N-methylformamide (rats), 746zomepirac glucuronide isomeric esters, characterization. 503
Obesity. acetaminophen disposition, overfed rat model. 674Omeprazole
oral dosesmain urinary metabolites. identification (rats, dogs). 341metabolic disposition (dogs. rats. mice), 336
ONO-802. metabolism. intravenous and vaginal administration. preg-nant women, 494
Oxazepam. metabolic disposition (rats). 41Oxidation
acetylation or. seromucoids (rats). 663taurine conjugation. biliary excretion, trimoprostil metabolites (rats),
465
Parathion. biotransformation factors. isolated perfused liver (mice). 214Pesticides. parathion. biotransformation factors. liver (mice). 214Phencyclidine. disposition alteration. Fab fragments (dogs). 52Phenytoin. deutenum-labeled and unlabeled, pharmacokinetic equiva-
lence. 509Physostigmine. hepatic and muscle clearance (rats). I 83Placenta
benzo(a)pyrene, positional metabolism. maternal liver (rats), 471carcinogens/atherogens
phase II biotranformation. 3-hydroxy-benzo(a)pyrene glucuronida-tion (rats, cockerels, man). 293
phase II biotransformation (rats, cockerels). 287
transfer. quazepam (mice). 310Plasma. brain and. bupropion and metabolites (rats. mice. guinea pigs),
692Polyethylene glycol-L-asparaginase. clinical pharmacology(humans). 349Polymorphisms
hereditary acetylation. molecular basis (rabbits. hamster. humans). 377N-acetylation. predictors (rabbits), 382
Pregnancy. ONO-802 metabolism. intravenous and vaginal administra-tion. 494
Promazine. chlopromazine. major plasma metabolite, chronic schizo-phrenics (man). 263
Propranolol
altered disposition. adjuvant-induced arthritis (rats). 482metabolite. 3-(4-hydroxy-l-napthoxy)lactic acid. synthesis and identi-
fication (rat. man). 202stereoselective metabolism. 506
2-n-Propyl-4-pentenoic acid. metabolic fate of valproic acid (monkeys).
443. 454
Pseudoracemic mixtures, propranolol. stereoselective metabolism. 506
Quazepam. placental transfer (mice). 310
Ranitidinecimetidine or. pretreatment. hepatic mixed function oxidase activity
(rats). 580drug interaction (rats). 649
13-cis-Retinoic acid. isomerization. 698
aII-trans-Retinoic acid. isomerization. 698
Rifampin. a-acid glycoprotein. antipyrine clearance. kinetics of induc-tion (dogs). 46
Schizophrenia. chronic. promazine. major plasma metabolite of chlor-promazine (man), 263
Seromucoids. relationship. rate of oxidation or acetylation of substrates(rats). 663
Serum. N-(4-hydroxyphenyl)-all-trans-retinamide. pharmacokinetics(rats, mice), 714
Sex. age effect and. theophylline. elimination kinetics (rabbits). 372SK&F 86466. pharmacokinetics. metabolism and disposition (rats. dogs).
540
SKF 525A. cimetidine or. pretreatment. hepatic mixed function oxidase
activity(rats).580
Stiripentol. metabolic fate (humans). 654Sulfamethazine
depletion kinetics (swine). I 61steady state kinetics (swine). I 55
Sulfate. conjugate. diflunisal. new major metabolite (humans), I 27Sulfation. inhibited glucuronidation and. dibutyryl cyclic AMP. hepato-
cytes (rats. guinea pigs). 526Sulfhydryl groups, a//-trans- and I 3-cis-retinoid nonenzymatic isomeri-
zation. 698Sulfur. metabolites, l,4-dibromobutane, biotransformation (rats), 608
Taurine. conjugation and oxidation. biliary excretion, trimoprostil me-
tabolites (rats). 465Testosterone
metabolism, cylosolic androgen binding assays. liver (rats). 366unusual metabolite (rats), 559
2.3.7.8-Tetrachlorodibenzo-p-dioxin. distribution and excretion, Ah lo-
cus effect (mice), 34Tetrahydrocannabinol. pharmacokinetics. following single or multiple
intravenous doses (rabbits), 230Tetrahydrothiophene. 1.4-dibromobutane biotransformation (rats), 608Theophylline. elimination kinetics. age and sex effects (rabbits). 372Thiol. environment regulation. N.N-dimethyl-4-aminoazobenzene, liver
microsomes (rats). 13Thiol methyltransferase. liver (mice), 680
Toluene. metabolites. covalent binding. liver microsomes (rats). 386Tracazolate. metabolites. urine (dogs. rats). 631Transacylation. cytosol-catalyzed. chlorinated N-hydroxy-N-acyl-ami-
nobiphenyl ethers (rats). 487Trimoprostil. identification of metabolites. bile excretion, oxidation and
taurine conjugation (rats). 465T-2 toxin. pharmacokinetics. HT-2 toxin metabolite. i.v. administration
(dogs). 250
U DP-glucuronic acid. hepatic glutathione and adenosine 3 ‘-phosphate-5 ‘-phosphosulfate concentrations, decreased energy production
(rats). 190UDP-glucuronosyltransferase. monooxygenase and. induction, hepato-
cyte primary cultures (rats). 353Urinary metabolite
hopantenic acid �i-glucoside. calcium hopantenate (dogs). 740
N-methyl-N’-oxonicotinium ion. isolation and characterization
(guinea pigs). 574Urine
ethimizol disposition (rats, mice). 718
flow dependence of renal clearance. physiochemical drug properties(rats). 239
metabolites. omeprazole oral dose (rats. dogs). 341tracazolate metabolism (dogs. rats). 631
Valproic acid
13-glucuronidase-resistant “glucuronides”. impaired biliary elimination(rats). 255
